{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:19:23Z","timestamp":1790795963068,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Sj\u00f6gren-Erkrankung (Sj\u00f6gren\u2019s Disease, SjD) ist eine chronisch-entz\u00fcndliche Autoimmunerkrankung, von der \u00fcberwiegend Frauen betroffen sind, die vor allem unter Trockenheit der Schleimh\u00e4ute, insbesondere im Augen- und Mundbereich, M\u00fcdigkeit und potentiell auch extraglandul\u00e4ren Manifestationen wie Gelenk- und Muskelschmerzen leiden. Bei der initialen Diagnostik spielen neben der Klinik serologische Ver\u00e4nderungen, speziell Autoantik\u00f6rper gegen SS-A(Ro)\/SS-B(La) sowie Rheumafaktoren eine wichtige Rolle. Die Pathogenese ist zwar noch nicht abschlie\u00dfend gekl\u00e4rt, von einer bedeutenden Rolle von B\u2011Zellen ist aber auszugehen. Bisher gab es vor allem symptomatische Therapiem\u00f6glichkeiten, die glandul\u00e4ren Funktionsdefizite bez\u00fcglich der Sicca-Symptomatik zu behandeln. Basierend auf den letzten Publikationen besteht berechtigte Hoffnung, dass sich dies bez\u00fcglich der extraglandul\u00e4ren Manifestationen bald \u00e4ndern k\u00f6nnte. Daf\u00fcr ist es besonders wichtig, dass validierte Outcome-Parameter zur Verf\u00fcgung stehen, mit denen der m\u00f6gliche Erfolg von neuen Therapien evaluiert werden kann. In diesem Beitrag werden die von der EULAR (European Alliance of Associations for Rheumatology) bereitgestellten Werkzeuge EULAR Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI) zur Erfassung der extraglandul\u00e4ren und  Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI) bzgl. der patientenberichteten Outcomes (PRO) \u00fcbersetzt und im Detail vorgestellt. Beide stellen auch die Grundpfeiler m\u00f6glicher Outcome-Instrumente (STAR bzw. CRESS) der 2.\u00a0Generation, die derzeit validiert werden, dar.<\/jats:p>","DOI":"10.1007\/s00393-026-01799-0","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:28:59Z","timestamp":1775827739000},"page":"527-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Praktisches Management der Sj\u00f6gren-Erkrankung im Zeitalter neuer Therapieoptionen","Practical management of Sj\u00f6gren\u2019s disease in the era of new treatment options"],"prefix":"10.1007","volume":"85","author":[{"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1799_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","volume":"21","author":"M Ramos-Casals","year":"2025","unstructured":"Ramos-Casals\u00a0M, Baer\u00a0AN, Brito-Zer\u00f3n\u00a0MDP, Hammitt\u00a0KM, Bouillot\u00a0C, Retamozo\u00a0S, Mackey\u00a0A, Yarowsky\u00a0D, Turner\u00a0B, Blanck\u00a0J, Fisher\u00a0BA, Akpek\u00a0EK, Baldini\u00a0C, Bootsma\u00a0H, Bowman\u00a0SJ, D\u00f6rner\u00a0T, Laing\u00a0L, Lieberman\u00a0SM, Mariette\u00a0X, Pflugfelder\u00a0SC, Sankar\u00a0V, Sis\u00f3-Almirall\u00a0A, Tzioufas\u00a0AG, Anaya\u00a0JM, Arma\u011fan\u00a0B, Bombardieri\u00a0M, Carsons\u00a0S, de Vita\u00a0S, Fox\u00a0RI, Gerli\u00a0R, Giacomelli\u00a0R, Gottenberg\u00a0JE, Hern\u00e1ndez-Molina\u00a0G, Jonsson\u00a0R, Kruize\u00a0A, Kwok\u00a0SK, Li\u00a0X, McCoy\u00a0SS, Ng\u00a0WF, Olsson\u00a0P, Rischmueller\u00a0M, Saraux\u00a0A, Scofield\u00a0RH, Valim\u00a0V, Vitali\u00a0C, Vivino\u00a0F, Wahren-Herlenius\u00a0M, Moutsopoulos\u00a0HM, International Task Force on Nomenclature of Sj\u00f6gren Disease (2025) 2023 International Rome consensus for the nomenclature of Sjoegren disease. Nat Rev Rheumatol 21:426\u2013437","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"1799_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette\u00a0X, Criswell\u00a0LA (2018) Primary Sj\u00f6gren\u2019s syndrome. N Engl J Med 378(10):931\u2013939","journal-title":"N Engl J Med"},{"issue":"25","key":"1799_CR3","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards\u00a0JC, Szczepanski\u00a0L, Szechinski\u00a0J, Filipowicz-Sosnowska\u00a0A, Emery\u00a0P, Close\u00a0DR, Stevens\u00a0RM, Shaw\u00a0T (2004) Efficacy of B\u2011cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572\u20132581","journal-title":"N Engl J Med"},{"issue":"8","key":"1799_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103837","volume":"24","author":"B Frade-Sosa","year":"2025","unstructured":"Frade-Sosa\u00a0B, Sarmiento-Monroy\u00a0JC, Bruce\u00a0IN, Arnaud\u00a0L, G\u00f3mez-Puerta\u00a0JA (2025) Dual B\u2011cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab. Autoimmun Rev 24(8):103837","journal-title":"Autoimmun Rev"},{"key":"1799_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127417","volume":"14","author":"Q Zhan","year":"2023","unstructured":"Zhan\u00a0Q, Zhang\u00a0J, Lin\u00a0Y, Chen\u00a0W, Fan\u00a0X, Zhang\u00a0D (2023) Pathogenesis and treatment of Sjogren\u2019s syndrome: Review and update. Front Immunol 14:1127417","journal-title":"Front Immunol"},{"issue":"8","key":"1799_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrrheum.2009.141","volume":"5","author":"T D\u00f6rner","year":"2009","unstructured":"D\u00f6rner\u00a0T, Radbruch\u00a0A, Burmester\u00a0GR (2009) B\u2011cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5(8):433\u2013441","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1799_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","volume":"42","author":"FB Vivino","year":"2016","unstructured":"Vivino\u00a0FB, Carsons\u00a0SE, Foulks\u00a0G, Daniels\u00a0TE, Parke\u00a0A, Brennan\u00a0MT, Forstot\u00a0SL, Scofield\u00a0RH, Hammitt\u00a0KM (2016) New Treatment Guidelines for Sj\u00f6gren\u2019s Disease. Rheum Dis Clin North Am 42(3):531\u2013551","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"1799_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals\u00a0M, Brito-Zer\u00f3n\u00a0P, Bombardieri\u00a0S, Bootsma\u00a0H, De Vita\u00a0S, D\u00f6rner\u00a0T, Fisher\u00a0BA, Gottenberg\u00a0JE, Hernandez-Molina\u00a0G, Kocher\u00a0A, Kostov\u00a0B, Kruize\u00a0AA, Mandl\u00a0T, Ng\u00a0WF, Retamozo\u00a0S, Seror\u00a0R, Shoenfeld\u00a0Y, Sis\u00f3-Almirall\u00a0A, Tzioufas\u00a0AG, Vitali\u00a0C, Bowman\u00a0S, Mariette\u00a0X, EULAR-Sj\u00f6gren Syndrome Task Force Group (2020) EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 79(1):3\u201318","journal-title":"Ann Rheum Dis"},{"key":"1799_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1543-z","volume":"18","author":"SQ Wang","year":"2017","unstructured":"Wang\u00a0SQ, Zhang\u00a0LW, Wei\u00a0P, Hua\u00a0H (2017) Is hydroxychloroquine effective in treating primary Sjogren\u2019s syndrome: a\u00a0systematic review and meta-analysis. BMC Musculoskelet Disord 18:186","journal-title":"BMC Musculoskelet Disord"},{"key":"1799_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"J Gottenberg","year":"2014","unstructured":"Gottenberg\u00a0J, Ravaud\u00a0P, Pu\u00e9chal\u00a0X et\u00a0al (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the Joquer randomized clinical trial. JAMA 312:249\u2013258","journal-title":"JAMA"},{"issue":"9","key":"1799_CR11","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1007\/s10067-025-07583-w","volume":"44","author":"K Zhu","year":"2025","unstructured":"Zhu\u00a0K, Zhang\u00a0X, Chen\u00a0G, Zhu\u00a0Y, Wang\u00a0K, Zhang\u00a0Q, Jin\u00a0Z, Shu\u00a0Q, Tang\u00a0X, Chen\u00a0H, Wang\u00a0D, Shen\u00a0W, Sun\u00a0L (2025) Treatment effectiveness of hydroxychloroquine in patients with primary Sj\u00f6gren\u2019s syndrome: a\u00a0real-world Study. Clin Rheumatol 44(9):3591\u20133603","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1799_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00393-024-01493-z","volume":"83","author":"Z N","year":"2024","unstructured":"N\u00a0Z, T\u00a0W, D\u00a0E (2024) Update Sj\u00f6gren-Syndrom : Diagnostik, Therapie und Fallstricke [Update on Sj\u00f6gren\u2019s syndrome : Diagnostics, treatment, and challenges]. Z Rheumatol 83(3):217\u2013228","journal-title":"Z Rheumatol"},{"issue":"5","key":"1799_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner\u00a0T, Posch\u00a0MG, Li\u00a0Y, Petricoul\u00a0O, Cabanski\u00a0M, Milojevic\u00a0JM, Kamphausen\u00a0E, Valentin\u00a0MA, Simonett\u00a0C, Mooney\u00a0L, H\u00fcser\u00a0A, Gram\u00a0H, Wagner\u00a0FD, Oliver\u00a0SJ (2019) Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 78(5):641\u2013647","journal-title":"Ann Rheum Dis"},{"issue":"10320","key":"1799_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman\u00a0SJ, Fox\u00a0R, D\u00f6rner\u00a0T, Mariette\u00a0X, Papas\u00a0A, Grader-Beck\u00a0T, Fisher\u00a0BA, Barcelos\u00a0F, De Vita\u00a0S, Schulze-Koops\u00a0H, Moots\u00a0RJ, Junge\u00a0G, Woznicki\u00a0JN, Sopala\u00a0MA, Luo\u00a0WL, Hueber\u00a0W (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399(10320):161\u2013171","journal-title":"Lancet"},{"issue":"5","key":"1799_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.43059","volume":"77","author":"T D\u00f6rner","year":"2025","unstructured":"D\u00f6rner\u00a0T, Bowman\u00a0SJ, Fox\u00a0R, Mariette\u00a0X, Papas\u00a0A, Grader-Beck\u00a0T, Fisher\u00a0BA, Barcelos\u00a0F, De Vita\u00a0S, Schulze-Koops\u00a0H, Moots\u00a0RJ, Junge\u00a0G, Woznicki\u00a0J, Sopala\u00a0M, Avrameas\u00a0A, Luo\u00a0WL, Hueber\u00a0W (2025) Safety and Efficacy of Ianalumab in Patients With Sj\u00f6gren\u2019s Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study. Arthritis Rheumatol 77(5):560\u2013570","journal-title":"Arthritis Rheumatol"},{"issue":"10452","key":"1799_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","volume":"404","author":"BA Fisher","year":"2024","unstructured":"Fisher\u00a0BA, Mariette\u00a0X, Papas\u00a0A, Grader-Beck\u00a0T, Bootsma\u00a0H, Ng\u00a0WF, van Daele\u00a0PLA, Finzel\u00a0S, Noaiseh\u00a0G, Elgueta\u00a0S, Hermann\u00a0J, McCoy\u00a0SS, Akpek\u00a0E, Bookman\u00a0A, Sopala\u00a0M, Montecchi-Palmer\u00a0M, Luo\u00a0WL, Scheurer\u00a0C, Hueber\u00a0W, TWINSS study group (2024) Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet 404(10452):540\u2013553","journal-title":"Lancet"},{"issue":"6","key":"1799_CR17","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","volume":"30","author":"EW St Clair","year":"2024","unstructured":"St Clair\u00a0EW, Baer\u00a0AN, Ng\u00a0WF, Noaiseh\u00a0G, Baldini\u00a0C, Tarrant\u00a0TK, Papas\u00a0A, Devauchelle-Pensec\u00a0V, Wang\u00a0L, Xu\u00a0W, Pham\u00a0TH, Sikora\u00a0K, Rees\u00a0WA, Alevizos\u00a0I (2024) CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a\u00a0randomized, double-blinded, placebo-controlled, phase\u00a02\u00a0trial. Nat Med 30(6):1583\u20131592","journal-title":"Nat Med"},{"issue":"7","key":"1799_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.ard.2025.05.004","volume":"84","author":"SJ Bowman","year":"2025","unstructured":"Bowman\u00a0SJ, Seror\u00a0R, Porcher\u00a0R, Arends\u00a0S, de Wolff\u00a0L, Verstappen\u00a0G, Devauchelle-Pensec\u00a0V, Jousse-Joulin\u00a0S, Baldini\u00a0C, Bombardieri\u00a0M, Pontarini\u00a0E, Hueber\u00a0W, Marvel\u00a0J, Goswami\u00a0P, Cornec\u00a0D, Fisher\u00a0BA, Nayar\u00a0S, Barone\u00a0F, Ng\u00a0WF, Gottenberg\u00a0JE, Bootsma\u00a0H, D\u00f6rner\u00a0T, Pincemin\u00a0M, Bouillot\u00a0C, Hammitt\u00a0KM, Wahren-Herlenius\u00a0M, van Roon\u00a0J, Nocturne\u00a0G, Laigle\u00a0L, Moingeon\u00a0P, Christodoulou\u00a0A, Sreih\u00a0AG, van Maurik\u00a0A, Chen\u00a0WH, Wisniacki\u00a0N, Piatrova\u00a0A, Jonsson\u00a0R, Gergely\u00a0P, Mariette\u00a0X (2025) Primary Sj\u00f6gren\u2019s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sj\u00f6gren\u2019s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI). Ann Rheum Dis 84(7):1068\u20131089","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1799_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror\u00a0R, Ravaud\u00a0P, Bowman\u00a0SJ, Baron\u00a0G, Tzioufas\u00a0A, Theander\u00a0E, Gottenberg\u00a0JE, Bootsma\u00a0H, Mariette\u00a0X, Vitali\u00a0C, EULAR Sj\u00f6gren\u2019s Task Force (2010) EULAR Sjogren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren\u2019s syndrome. Ann Rheum Dis 69(6):1103\u20131109","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1799_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror\u00a0R, Ravaud\u00a0P, Mariette\u00a0X, Bootsma\u00a0H, Theander\u00a0E, Hansen\u00a0A, Ramos-Casals\u00a0M, D\u00f6rner\u00a0T, Bombardieri\u00a0S, Hachulla\u00a0E, Brun\u00a0JG, Kruize\u00a0AA, Praprotnik\u00a0S, Tomsic\u00a0M, Gottenberg\u00a0JE, Devauchelle\u00a0V, Devita\u00a0S, Vollenweider\u00a0C, Mandl\u00a0T, Tzioufas\u00a0A, Carsons\u00a0S, Saraux\u00a0A, Sutcliffe\u00a0N, Vitali\u00a0C, Bowman\u00a0SJ, EULAR Sj\u00f6gren\u2019s Task Force (2011) EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome. Ann Rheum Dis 70(6):968\u2013972","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1799_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","volume":"74","author":"R Seror","year":"2015","unstructured":"Seror\u00a0R, Theander\u00a0E, Brun\u00a0JG, Ramos-Casals\u00a0M, Valim\u00a0V, D\u00f6rner\u00a0T, Bootsma\u00a0H, Tzioufas\u00a0A, Solans-Laqu\u00e9\u00a0R, Mandl\u00a0T, Gottenberg\u00a0JE, Hachulla\u00a0E, Sivils\u00a0KL, Ng\u00a0WF, Fauchais\u00a0AL, Bombardieri\u00a0S, Valesini\u00a0G, Bartoloni\u00a0E, Saraux\u00a0A, Tomsic\u00a0M, Sumida\u00a0T, Nishiyama\u00a0S, Caporali\u00a0R, Kruize\u00a0AA, Vollenweider\u00a0C, Ravaud\u00a0P, Vitali\u00a0C, Mariette\u00a0X, Bowman\u00a0SJ, EULAR Sj\u00f6gren\u2019s Task Force (2015) Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74(5):859\u2013866","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1799_CR22","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror\u00a0R, Meiners\u00a0P, Baron\u00a0G, Bootsma\u00a0H, Bowman\u00a0SJ, Vitali\u00a0C, Gottenberg\u00a0JE, Theander\u00a0E, Tzioufas\u00a0A, De Vita\u00a0S, Ramos-Casals\u00a0M, D\u00f6rner\u00a0T, Quartuccio\u00a0L, Ravaud\u00a0P, Mariette\u00a0X, EULAR Sj\u00f6gren Task Force (2016) Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis 75(11):1945\u20131950","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1799_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","volume":"1","author":"R Seror","year":"2015","unstructured":"Seror\u00a0R, Bowman\u00a0SJ, Brito-Zeron\u00a0P, Theander\u00a0E, Bootsma\u00a0H, Tzioufas\u00a0A, Gottenberg\u00a0JE, Ramos-Casals\u00a0M, D\u00f6rner\u00a0T, Ravaud\u00a0P, Vitali\u00a0C, Mariette\u00a0X, Asmussen\u00a0K, Jacobsen\u00a0S, Bartoloni\u00a0E, Gerli\u00a0R, Bijlsma\u00a0JW, Kruize\u00a0AA, Bombardieri\u00a0S, Bookman\u00a0A, Kallenberg\u00a0C, Meiners\u00a0P, Brun\u00a0JG, Jonsson\u00a0R, Caporali\u00a0R, Carsons\u00a0S, De Vita\u00a0S, Del Papa\u00a0N, Devauchelle\u00a0V, Saraux\u00a0A, Fauchais\u00a0AL, Sibilia\u00a0J, Hachulla\u00a0E, Illei\u00a0G, Isenberg\u00a0D, Jones\u00a0A, Manoussakis\u00a0M, Mandl\u00a0T, Jacobsson\u00a0L, Demoulins\u00a0F, Montecucco\u00a0C, Ng\u00a0WF, Nishiyama\u00a0S, Omdal\u00a0R, Parke\u00a0A, Praprotnik\u00a0S, Tomsic\u00a0M, Price\u00a0E, Scofield\u00a0H, L Sivils\u00a0K, Smolen\u00a0J, Laqu\u00e9\u00a0RS, Steinfeld\u00a0S, Sutcliffe\u00a0N, Sumida\u00a0T, Valesini\u00a0G, Valim\u00a0V, Vivino\u00a0FB, Vollenweider\u00a0C (2015) EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide. RMD Open 1(1):e000022","journal-title":"RMD Open"},{"issue":"2","key":"1799_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror\u00a0R, Bootsma\u00a0H, Saraux\u00a0A, Bowman\u00a0SJ, Theander\u00a0E, Brun\u00a0JG, Baron\u00a0G, Le Guern\u00a0V, Devauchelle-Pensec\u00a0V, Ramos-Casals\u00a0M, Valim\u00a0V, D\u00f6rner\u00a0T, Tzioufas\u00a0A, Gottenberg\u00a0JE, Solans Laqu\u00e9\u00a0R, Mandl\u00a0T, Hachulla\u00a0E, Sivils\u00a0KL, Ng\u00a0WF, Fauchais\u00a0AL, Bombardieri\u00a0S, Priori\u00a0R, Bartoloni\u00a0E, Goeb\u00a0V, Praprotnik\u00a0S, Sumida\u00a0T, Nishiyama\u00a0S, Caporali\u00a0R, Kruize\u00a0AA, Vollenweider\u00a0C, Ravaud\u00a0P, Meiners\u00a0P, Brito-Zer\u00f3n\u00a0P, Vitali\u00a0C, Mariette\u00a0X, EULAR Sj\u00f6gren\u2019s Task Force (2016) Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75(2):382\u2013389","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1799_CR25","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends\u00a0S, de Wolff\u00a0L, van Nimwegen\u00a0JF, Verstappen\u00a0GMPJ, Vehof\u00a0J, Bombardieri\u00a0M, Bowman\u00a0SJ, Pontarini\u00a0E, Baer\u00a0AN, Nys\u00a0M, Gottenberg\u00a0JE, Felten\u00a0R, Ray\u00a0N, Vissink\u00a0A, Kroese\u00a0FGM, Bootsma\u00a0H (2021) Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol 3(8):e553\u2013e562","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"1799_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror\u00a0R, Baron\u00a0G, Camus\u00a0M, Cornec\u00a0D, Perrodeau\u00a0E, Bowman\u00a0SJ, Bombardieri\u00a0M, Bootsma\u00a0H, Gottenberg\u00a0JE, Fisher\u00a0B, Hueber\u00a0W, van Roon\u00a0JA, Devauchelle-Pensec\u00a0V, Gergely\u00a0P, Mariette\u00a0X, Porcher\u00a0R, NECESSITY WP5 - STAR development working group, NECESSITY WP5- STAR development working group (2022) Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 81(7):979\u2013989","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"1799_CR27","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.14219\/jada.archive.2008.0353","volume":"139","author":"M Navazesh","year":"2008","unstructured":"Navazesh\u00a0M, Kumar\u00a0SK, University of Southern California School of Dentistry (2008) Measuring salivary flow: challenges and opportunities. J\u00a0Am Dent Assoc 139(Suppl):35S\u201340S","journal-title":"J Am Dent Assoc"},{"issue":"9","key":"1799_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3899\/jrheum.2024-1012","volume":"52","author":"M Beydon","year":"2025","unstructured":"Beydon\u00a0M, Nguyen\u00a0Y, Gordon\u00a0R, Foulquier\u00a0N, Bouillot\u00a0C, Hammitt\u00a0KM, Bowman\u00a0SJ, Mariette\u00a0X, Cornec\u00a0D, McCoy\u00a0SS, Seror\u00a0R (2025) A Systematic Review of Clinical Trial Designs and Outcome Measures in Sj\u00f6gren Disease Randomized Controlled Trials. J\u00a0Rheumatol 52(9):858\u2013872","journal-title":"J Rheumatol"},{"issue":"1","key":"1799_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004753","volume":"11","author":"L de Wolff","year":"2025","unstructured":"de Wolff\u00a0L, Verstappen\u00a0G, Stel\u00a0A, van Zuiden\u00a0G, van Nimwegen\u00a0J, Vissink\u00a0A, Kroese\u00a0F, Arends\u00a0S, Bootsma\u00a0H (2025) Systemic disease activity measured with ESSDAI varies largely over 5\u00a0years in a\u00a0prospective, longitudinal cohort of patients with Sj\u00f6gren\u2019s disease. RMD Open 11(1):e004753","journal-title":"RMD Open"},{"issue":"7","key":"1799_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05909-0","volume":"45","author":"M Fern\u00e1ndez-Castro","year":"2025","unstructured":"Fern\u00e1ndez-Castro\u00a0M, Plaza-Almuedo\u00a0Z, Rosas\u00a0J, Mart\u00ednez-Taboada\u00a0V, Oliv\u00e9\u00a0A, Menor-Almagro\u00a0R, Serrano-Benavente\u00a0B, Font-Urgelles\u00a0J, Garc\u00eda-Aparicio\u00a0A, Manrique-Arija\u00a0S, Garc\u00eda-Vadillo\u00a0JA, L\u00f3pez-Gonz\u00e1lez\u00a0R, Narv\u00e1ez\u00a0J, Rodriguez-Lozano\u00a0B, Galisteo\u00a0C, Gonz\u00e1lez-Mart\u00edn\u00a0J, Vela-Casasempere\u00a0P, Boh\u00f3rquez\u00a0C, Erausquin\u00a0C, Paredes-Romero\u00a0B, Riancho-Zarrabeitia\u00a0L, Melchor-Diaz\u00a0S, Pego-Reigosa\u00a0JM, Heredia\u00a0S, Moriano\u00a0C, Blazquez-Ca\u00f1amero\u00a0MA, Estrada\u00a0P, J\u00fadez\u00a0E, Belzunegui\u00a0JM, Ramos\u00a0C, S\u00e1nchez-Alonso\u00a0F, Andreu\u00a0JL, Systemic Autoimmune Diseases Group of the Spanish Society of Rheumatology (EAS-SER) (2025) Long-term changes in Sj\u00f6gren\u2019s disease: a 9\u2011year prospective follow-up study from the SJOGRENSER Registry. Rheumatol Int 45(7):156","journal-title":"Rheumatol Int"},{"key":"1799_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/jcp.21.5.656","volume":"21","author":"DM Chisholm","year":"1968","unstructured":"Chisholm\u00a0DM, Mason\u00a0DK (1968) Labial salivary gland biopsy in Sjogren\u2019s disease. J\u00a0Clin Pathol 21:656\u2013660","journal-title":"J Clin Pathol"},{"issue":"6","key":"1799_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/art.1780370615","volume":"37","author":"TE Daniels","year":"1994","unstructured":"Daniels\u00a0TE, Whitcher\u00a0JP (1994) Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 37(6):869\u2013877","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01799-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:53:52Z","timestamp":1788944032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01799-0"}},"subtitle":["Aktueller Stellenwert der verf\u00fcgbaren Outcome-Parameter","Current value of available outcome parameters"],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01799-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Braun und T.\u00a0D\u00f6rner geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}